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Background and Purpose: The CT-DRAGON score was developed to predict
long-term functional outcome after acute stroke in the anterior circulation treated by
thrombolysis. Its implementation in clinical practice may be hampered by its plethora of
variables. The current study was designed to develop and evaluate an alternative score,
as a reduced set of features, derived from the original CT-DRAGON score.
Methods: This single-center retrospective study included 564 patients treated for
stroke, in the anterior and the posterior circulation. At 90 days, favorable [modified Rankin
Scale score (mRS) of 0–2] and miserable outcome (mRS of 5–6) were predicted by the
CT-DRAGON in 427 patients. Bootstrap forests selected the most relevant parameters of
the CT-DRAGON, in order to develop a reduced set of features. Discrimination, calibration
and misclassification of both models were tested.
Results: The area under the receiver operating characteristic curve (AUROC) for the
CT-DRAGON was 0.78 (95% CI 0.74–0.81) for favorable and 0.78 (95% CI 0.72-0.83)
for miserable outcome. Misclassification was 29% for favorable and 13.5% for miserable
outcome, with a 100% specificity for the latter. National Institutes of Health Stroke
Scale (NIHSS), pre-stroke mRS and age were identified as the strongest contributors
to favorable and miserable outcome and named the reduced features set. While
CT-DRAGON was only available in 323 patients (57%), the reduced features set could
be calculated in 515 patients (91%) (p < 0.001). Misclassification was 25.8% for
favorable and 14.4% for miserable outcome, with a 97% specificity for miserable
outcome. The reduced features set had better discriminative power than CT-DRAGON
for both outcomes (both p < 0.005), with an AUROC of 0.82 (95% CI 0.79–0.86)
and 0.83 (95% CI 0.77–0.87) for favorable and miserable outcome, respectively.
Lesenne et al. Comparison CT-DRAGON/Reduced Features in Stroke
Conclusions: The CT-DRAGON score revealed acceptable discrimination in our
cohort of both anterior and posterior circulation strokes, receiving all treatment
modalities. The reduced features set could be measured in a larger cohort and with
better discrimination. However, the reduced features set needs further validation in a
prospective, multicentre study.
Clinical Trial Registration: http://www.clinicaltrials.gov. Identifiers: NCT03355690,
NCT04092543.
Keywords: cerebrovascular disorders, stroke, prognosis, machine learning, thrombectomy, thrombolytic therapy
Subject terms: ischemic stroke, transient ischemic attack (TIA), mortality/survival, quality and outcomes,
revascularization, treatment
INTRODUCTION
With an incidence of 14 million patients annually, ischemic
stroke is the second largest cause of death globally after ischemic
heart disease. It has a major burden of morbidity as well, with
an estimated annual 52 million disability-adjusted life years (1).
Prognostic tools that predict outcome of acute ischemic stroke
potentially provide early identification of patients who are likely
to have a good or poor outcome despite treatment. If this tool
has a high specificity for miserable outcome, it could be helpful in
counseling patients and relatives, because estimations of outcome
in stroke patients remain largely subjective at this moment.
Moreover, and probably more applicable, these scores could be
used for case-mix adjustments for benchmarking purposes.
In this view, several prognostic scoring systems have been
developed to address this need, such as the ASTRAL, the CT-
DRAGON, the iSCORE and the PLAN score (2). However, they
have not been widely implemented in clinical practice, due to
several limitations. First, a large number of input variables is
required, some of which are hard to determine in the acute
setting. Second, these scores are often tailored to subpopulations
of stroke patients, depending on the localization of the stroke
and/or the treatment received. Third, there is still a lack of
validation in large patient populations using real world data,
which are more prone to missingness and inaccuracies.
Treatment options for acute stroke have strongly evolved over
the last decade. Most scoring systems were developed in the era
of thrombolysis, while thrombectomy and its combination with
thrombolysis only have been implemented over the last years (3–
9). These developments certainly should have influenced reliable
estimates of outcome and long-term effect of treatment.
To enhance implementation of prognostic tools, Fahey et al.
advised to validate existing prognostic tools in different patient
populations and treatment settings, opposed to designing new
ones (10). Notably the CT-DRAGON score (Dense Artery,
modified Rankin Scale, Age, Glucose, Onset-to-Treatment and
NIHSS) has already been validated in previous studies and
adapted to different diagnostics and treatments in stroke
patients (11–17). The MRI-DRAGON score was developed and
externally validated to deal with patients, in whom MRI was
used as the first-line diagnostic tool (18, 19). Recently, the
DRAGON score has also been modified to deal with patients,
undergoingmechanical thrombectomy (20). Thesemodifications
are relevant since decision to performmechanical thrombectomy
in patients with wake-up strokes is often based on MRI
diffusion-weighted imaging (DWI). Despite the modifications to
specific subpopulations of stroke patients, its potential remains
underutilized because of the missing data. A “light version” of
the DRAGON score with less input variables, selected bymachine
learning, might thus be an alternative.
Machine learning has many applications, among which
prediction of outcomes in healthcare. Machine learning
techniques consist of algorithms able to solve problems by
learning from experiences. Mathematical models are built and
trained by providing training data. When new data are supplied,
the models are able to generalize their learned expertise and
make accurate predictions. Dimensionality reduction is a more
recent application of machine learning. This process strives to
reduce the number of variables under consideration. By “feature
selection” input variables from existing scoring systems can be
reduced and optimized (21, 22). With a reduced features set
dynamic predictive models can be built, deployed and monitored
over time.
We aimed to validate the CT-DRAGON score in all ischemic
stroke localizations and for all treatment options, including a
conservative treatment policy. The predictive power was then
compared with a model, that included a set of the individual
components of the CT-DRAGON score, selected by machine
learning techniques.
METHODS
Patient Population
This retrospective observational study included patients
admitted to the stroke center of Ziekenhuis Oost-Limburg
Genk, Genk, Belgium from January 2017 until February 2019.
Patients with hemorrhagic stroke and stroke mimics were
excluded. The final cohort comprised not only patients with
acute ischemic stroke independent of pre-stroke mRS, stroke
localization or treatment, but also patients with transient
Frontiers in Neurology | www.frontiersin.org 2 July 2020 | Volume 11 | Article 718
Lesenne et al. Comparison CT-DRAGON/Reduced Features in Stroke
ischaemic attack (TIA) with symptoms on admission. These
patients with TIA were included in the analysis, since its final
diagnosis is often impossible to establish in an acute time
frame. Treatment of stroke patients was categorized into (1)
conservative therapy, (2) thrombolysis, (3) thrombectomy,
or (4) a combination of thrombolysis and thrombectomy.
This study was approved by the institutional review board of
Ziekenhuis Oost-Limburg, Genk (19/0059U) and registered on
ClinicalTrials.gov (NCT03355690, NCT04092543).
Outcome Measure
Functional outcome was determined by the mRS score at 3
months. Patients were contacted by telephone within a timeframe
of 3 months ± 2 weeks by the independent stroke study
collaborator (EV) who was not involved in the care of the
patients. Favorable outcome was defined as a mRS of 0, 1, or 2,
miserable outcome as a mRS of 5 or 6 (11).
Prediction Models
Data necessary for the calculation of the CT-DRAGON score
were collected through a search of the electronic patient files. CT
scans were evaluated by dedicated radiologists for the presence
of a large vessel occlusion and early signs of infarction. A
thrombus in the internal carotid artery or in the M1 or M2
segment of the middle cerebral artery on CT angiography was
included in the score and was regarded as an alternative to
the hyperdense cerebral artery sign (1 point). For strokes in
the posterior circulation, the same principle was applied for an
occlusion in the vertebral or basilar artery (1 point).
For ischemic strokes in the vascular territory of the medial
cerebral artery, early infarct signs were scored (1 point) when
the Alberta Stroke Program Early CT score (ASPECTS) was<10.
For all other vascular territories, any signs of early ischemia on
CT scored 1 point. Early infarct signs on CT were defined as
hypodense areas in any cerebral artery territory in combination
with effacement of the adjacent sulci and loss of differentiation
between gray and white matter.
As the sample size of the dataset was fixed, it was decided
that the ratio of events (favorable or miserable outcome) per each
candidate predictive factor should be at least 10.
While “time onset stroke to treatment” was one of the
parameters in the original CT-DRAGON score, we used “time
onset stroke to emergency department admission” as we did not
want to exclude patients who received conservative treatment.
When the time of onset was unknown, it was assumed to be more
than 90min and thus scoring 1 point. In this way a complete-
case analysis was employed, with missing data from the other
parameters of the CT-DRAGON recoded as 0 points. While this
rigid, arbitrary imputation of missing values is clinically intuitive,
it may inherently induce bias as the data are most likely not
missing at random.
Through machine learning techniques, we selected the
parameters of the CT-DRAGON score that did or did not provide
additional predictive value. By use of logistic regression, decision
tree analysis (maximum of 4 splits) and bootstrap forest in
sequential order a reduced features set with the most powerful
predictors of the CT-DRAGON was built. The 7 components
of the CT-DRAGON score were added into the models as a
continuum over the entire range of the values (age in years,
NIHSS in ordinal points, pre-stroke mRS in ordinal points,
glycaemia in mg/dL, time to emergency department in hours).
Early ischaemia (yes/no) and dense artery sign or its posterior
equivalent (yes/no) were entered as dichotomous values. The
three models were only used to assess the consistency of the
prognostic factors in terms of selection. The ranking of factors
was done by bootstrap forests to generate the contributions.
This process was run three times and the average was taken.
The number of elements for the reduced features set was not
predefined. Instead, the cumulative relative contribution to the
outcome had to be at least 80%, when combining the factors with
the highest relative contribution. The bootstrap forest analysis
fits an ensemble model by averaging many decision trees each
of which is fit to a bootstrap sample of the training data. Each
split in each tree considers a random subset of the predictors. In
this way, many weak models are combined to produce a more
powerful model. Aminimum of 10 splits per tree and aminimum
size of 5 per tree was used.
We then tested the reduced features set in a training
and a validation cohort. Baseline patient characteristics were
compared between training and validation cohorts. Finally, the
predictive performance of the CT-DRAGON and the reduced
features set were compared for discrimination, calibration and
misclassification. For these analyses patients, in whom the mRS
at 90 days was missing, were excluded.
Statistical Analyses
The distribution of data was analyzed. All data were represented
as either mean +/− SD or median and IQR. A training (0.75
of study cohort) and a validation cohort (0.25) were established
by random selection. We assessed the performance of the CT-
DRAGON and the reduced features set with the variance and the
AUROC for both favorable and miserable outcomes. Calibration
of the model was tested by lack of fit. Misclassification rate,
sensitivity and specificity were calculated. We estimated the
fit of the model with the Akaike Information criterion (AIC).
Analyses were performed in JMP Pro, version 14.1.0 (SAS
Institute Inc, Cary, NC, USA). Two-sided P < 0.05 were deemed
statistically significant.
RESULTS
Descriptive Statistics
From January 2017 to February 2019 a total of 904 patients
with stroke symptoms were admitted (Figure 1). Of these, 564
were diagnosed with ischemic stroke or TIA with symptoms
on admission. The mean age was 73 years (SD 13) and 296
(52%) patients were male (Table 1). The median NIHSS on
admission was 6 (IQR 3–14). Three hundred and forty-four
(61%) patients received conservative treatment. This represents
a heterogeneous group of patients with on the one hand no
indication for thrombolysis or thrombectomy due to the low
severity of the stroke and on the other hand patients with
severe symptoms and contraindications for treatment. Ninety-
six (17%) patients received thrombolysis, 71 (13%) patients
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FIGURE 1 | Flowchart of patients.
underwent thrombectomy and 53 (9%) patients were treated with
the combination of thrombolysis and thrombectomy.
One hundred eighty-two (32%) patients suffered a stroke in
the anterior cerebral circulation. Twelve (2%) patients had a
proximal posterior ischemic stroke, 280 (50%) had a lacunar
infarction and in 90 (16%) patients no large vessel occlusion
could be visualized. The validation cohort did not differ from the
training cohort for baseline characteristics (Appendix D).
The mean CT-DRAGON score for the whole population
was 4 ± 2. The mean CT-DRAGON scores, subdivided by
treatment group, are represented in Table 2. The scores were
different between the thrombectomy (± thrombolysis) and the
thrombolysis or the conservative treatment group (p < 0.0001).
While mRS at 3 months was missing in 137 (24%) cases,
mortality (16%, mRS 6) was available for all patients (Table 3).
Two hundred and forty-six (58%) patients had a favorable
outcome (mRS 0–2). Eighty-four (19%) patients had a miserable
outcome (mRS 5–6).
Development of the Proposed Reduced
Features Set
Logistic regression, bootstrap forest and decision tree analysis
showed comparable performance of the individual components
in determining both favorable and miserable outcome. Age,
NIHSS and pre-stroke mRS were the most predictive parameters
from the CT-DRAGON score in bootstrap forest analysis, with
a proportional contribution to the outcome of 87% for the
prediction of favorable outcome and 85% for the prediction of
miserable outcome (Table 4). The reduced features set could be
calculated in 515 patients (91%) in comparison with the CT-
DRAGON score, which could only be determined in 323 patients
(57%) (p < 0.001).
Analytical Statistics
The AUROC for the CT-DRAGON score in predicting
favorable outcome was 0.78 (95% CI 0.74–0.81) (Table 5).
For predicting miserable outcome, it was 0.78 (95% CI
0.72–0.83). The misclassification rate of the CT-DRAGON
in predicting favorable and miserable outcome was 29 and
13.5%, respectively. Sensitivity and specificity were 67 and
74% in the prediction of favorable and 10 and 100% in the
prediction of miserable outcome. R2 was 0.30 (lack of fit p
= 0.91) and 0.22 (lack of fit p = 0.76) for the prediction
of favorable and miserable outcome, respectively, by the
CT-DRAGON score.
We found an AUROC of 0.82 (95% CI 0.79–0.86) and
0.83 (95% CI 0.77–0.87) in predicting favorable and miserable
outcome, respectively, based on age, NIHSS and pre-stroke mRS
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TABLE 1 | Baseline patient characteristics.
N = 564 Missings, n
Age, years, mean (SD) 73 (13)
Sex, n (%)
Male 296 (52)
National Institutes of Health Stroke
Scale (NIHSS), median (IQR)
6 (3–14) 29
Glycemia, mg/dL, mean (SD) 128 (44) 46
Time onset stroke to emergency
department (ED) admission, hours,
median (IQR)
1.7 (0.9–3.8) 184
Localization, n (%)
Anterior 182 (32)
Posterior proximally 12 (2)
Lacunar 280 (50)
No large vessel occlusion 90 (16)
Pre-stroke modified Rankin Scale
score (mRS), n (%)
39
0 237 (45)
1 158 (30)
2 49 (9)
3 54 (10)
4 19 (4)
5 8 (2)
Hyperdense artery/vessel occlusion,
n (%)
194 (34)
Alberta Stroke Program Early CT
score (ASPECTS), n (%)
<10 149 (34)
Early infarct signs, n (%)
Yes 39 (35)
ASPECTS + early infarct signs, n 16
CT-DRAGON score, mean (SD) 4 (2) 241
Treatment, n (%)
Conservative treatment 344 (61)
Thrombectomy 71 (13)
Thrombolysis 96 (17)
Thrombectomy + thrombolysis 53 (9)
(the reduced features set). Misclassification rates were 25.8%
for favorable and 14.4% for miserable outcome. Sensitivity and
specificity were 77 and 73%, respectively, in the prediction of
favorable and 23 and 97%, respectively, in the prediction of
miserable outcome. R2 was 0.42 (lack of fit p = 0.34) and 0.29
(lack of fit p = 1.0) for the prediction of favorable and miserable
outcome, respectively, by the reduced features set. However, the
discrimination of the reduced features set was lower in the patient
population in which the CT-DRAGON could be calculated (n
= 323) with an AUROC of 0.78 for favorable and 0.79 for
miserable outcome.
For the prediction of favorable and miserable outcome,
the AIC was 632 and 397, respectively, based on the CT-
DRAGON and 528 and 346, respectively, based on the reduced
features set.
TABLE 2 | Patient characteristics by treatment.
N = 564 Conservative
(n = 344)
Thrombectomy
(n = 71)
Thrombolysis
(n = 96)
Combination
(n = 53)
Age years, mean (SD) 74 (13) 74 (14) 72 (14) 75 (13)
Sex, n (%)
Male 188 (55) 33 (46) 50 (52) 25 (47)
NIHSS, median (IQR) 4 (2–8) 17 (14–22) 6 (4–12) 16 (10–20)
Minor stroke (NIHSS < 4),
n (%)
151 (45) 5 (8) 22 (24) 2 (4)
Glycemia, mg/dL, mean
(SD)
128 (46) 136 (40) 123 (45) 125 (38)
Time onset stroke to ED,
hours, median (IQR)
2.5 (1.1–5) 1.7 (0.8–3.2) 1.2 (0.7–2,1) 1.3 (0.8–3.3)
Localization, n (%)
Anterior 50 (15) 63 (89) 32 (33) 48 (91)
Posterior proximally 2 (1) 6 (8) 2 (2) 3 (5)
Lacunar 222 (64) 2 (3) 50 (52) 2 (4)
No large vessel occlusion 70 (20) 0 12 (13) 0
Pre-stroke mRS, median
(IQR)
1 (0–2) 1 (0–2) 1 (0–1) 0 (0–1)
ASPECTS, n (%)
<10 81 (31) 25 (48) 16 (20) 27 (60)
10 179 (69) 27 (52) 65 (80) 18 (40)
Early infarct signs, n (%)
Yes 28 (36) 6 (50) 1 (7) 4 (80)
No 50 (64) 6 (50) 14 (93) 1 (20)
CT-DRAGON, mean (SD) 3 (2) 6 (2) 3 (2) 6 (2)
TABLE 3 | Modified rankin scale score at 90 days.
N = 427
Missings: n = 137 N Proportion
0 97 23%
1 104 24%
2 45 11%
3 44 10%
4 53 12%
5 14 3%
6 70 16%
DISCUSSION
This study could confirm that the CT-DRAGON score is
a useful and validated tool to predict long-term functional
outcome after acute ischemic stroke. Yet the collection of
all necessary input data for this score seems challenging in
a real-world setting. Dimensionality reduction of the rather
complex CT-DRAGON score yielded a reduced features set
with similar predictive characteristics. Its input parameters (age,
NIHSS and pre-stroke mRS) can be rapidly obtained by history
taking and clinical neurological examination, leading to a much
broader implementation potential. It hence does not depend on
radiological findings, which require a specialist’s evaluation.
The original CT-DRAGON score and the reduced features set
were validated together in a well-controlled single-center dataset
of patients, who suffered from anterior or posterior circulation
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TABLE 4 | Feature selection by bootstrap forest for favorable and miserable
outcome.
Predictor Contribution Proportion Rank
FAVORABLE OUTCOME VS. OTHER
NIHSS 20.21 0.40 1
Pre-stroke mRS 13.78 0.27 2
Age 10.14 0.20 3
Glycemia 3.99 0.08 4
Time onset to ED admission 1.81 0.03 5
Early infarct signs 1.13 0.02 6
MISERABLE OUTCOME VS. OTHER
NIHSS 14.76 0.43 1
Pre-stroke mRS 9.12 0.27 2
Age 5.03 0.15 3
Glycemia 2.78 0.08 4
Time onset to ED admission 2.18 0.06 5
Early infarct signs 0.40 0.01 6
TABLE 5 | Area under the receiver operating characteristic curve (AUROC),
misclassification rate, sensitivity, specificity, variance, and Akaike Information
Criterion (AIC) of the CT-DRAGON and the reduced features set.
Favorable outcome vs.
other
Miserable outcome vs.
other
CT-DRAGON
score
AUROC 0.78 (95% CI
0.74–0.81)
Misclassification rate 29%
Sensitivity 67%
Specificity 74%
R2 0.30
AIC 632
AUROC 0.78 (95% CI
0.72–0.83)
Misclassification
rate 13.5%
Sensitivity 10%
Specificity 100%
R2 0.22
AIC 397
Reduced features
set
AUROC 0.82 (95% CI
0.79–0.86)
Misclassification rate
25.8%
Sensitivity 77%
Specificity 73%
R2 0.42
AIC 528
AUROC 0.83 (95% CI
0.77–0.87)
Misclassification rate
14.4%
Sensitivity 23%
Specificity 97%
R2 0.29
AIC 346
or lacunar strokes, treated with all modalities, including
basic antiplatelet therapy. It has already been shown that
discrimination does not differ between anterior and posterior
strokes in a large cohort of patients, who received intravenous
thrombolysis, with a AUROC of approximately 0.83 (12). A
small study validated the DRAGON score in patients treated
with the combination of thrombolysis and thrombectomy (14).
However, neither the AUROC was calculated, nor a development
and validation cohort were used. The predictive performance of
the CT-DRAGON in the large multicentre Safe Implementation
of Thrombolysis in Stroke-International Stroke Thrombolysis
Register (SITS-ISTR) showed a similar specificity of 74.1–99.7%
for the prediction of good and poor outcome (13). The CT-
DRAGON score also had a better discrimination for miserable
outcome (AUROC 0.89) than for good outcome (AUROC 0.79)
in a Danish cohort of patients undergoing IV thrombolysis
(15). The predictive performance (AUROC 0.84) of the CT-
DRAGON score in a Spanish cohort with more severe strokes
was comparable to the latter external validation studies (16). The
discrimination of the CT-DRAGON for good (AUROC 0.73) and
miserable (AUROC 0.75) outcome was lower compared to the
previous studies and more in line with our study (17). The lower
predictive performance is partially explained by a lower number
of patients with high CT-DRAGON scores (>7). Our study also
included many patients with relatively low CT-DRAGON scores,
with only 10% of the patients having a CT-DRAGON score
of >7. Taking together the entire body of external validation
studies, the CT-DRAGON score can be implemented for the
prognostication of functional outcome after acute ischemic
stroke. However, the score seems to perform better in patient
with more severe strokes.
Whether the CT-DRAGON score has a better discrimination
in patients undergoing thrombectomy, whether or not in
combination with thrombolysis, could not be determined in our
study, as the number of these patients was too low for subgroup
analyses. It can be assumed that the AUROCwill at least be in line
with the one of the patients undergoing thrombolysis for strokes
with higher severity. The study by Ovesen showed that in patients
with a M1 occlusion, a typical indication for thrombectomy, the
AUROC of the CT-DRAGON score for miserable outcome was
0.89 (15).
Despite these merits, the CT-DRAGON is not being applied
routinely in daily practice. The lack of availability of some
variables at admission and the number of parameters is a
potential limitation for clinicians in a usually busy emergency
department. This is reflected in the large number of missing
values in our data, which excludes patients and their relatives
to have benefit from prognostication and which may introduce
significant bias into outcome data. Missing values are rarely
random in a clinical context and multiple data imputation
to account for missing values, is not a practical solution
in daily clinical practice. Practical assumptions on missing
data, as we used in our study, may on the other hand lead
to underestimation of the CT-DRAGON score, undermining
its potential.
We therefore used the principle of dimensionality reduction to
select the features from the CT-DRAGON score which contribute
the most to the predictive power of the original score. The
selection of the most predictive parameters—NIHSS, age and
pre-stroke modified Rankin Scale—was done by bootstrap forest.
In this machine learning process, missingness is also taken
into account. This is a confirmation of the development of the
original CT-DRAGON score by logistic regression (11). Here
the variables associated with the strongest regression coefficients
were also NIHSS, age and pre-stroke mRS. It indicates that
the strongest predictors for functional outcome remained stable,
even after the introduction of thrombectomy and the inclusion
of patients with posterior strokes in the study population, and it
underpins the validity of the core of the CT-DRAGON score.
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This reduced features set could be scored in a larger
proportion of the stroke population, increasing its
generalizability and applicability in patients suffering from
posterior circulation and lacunar strokes as well. Additionally,
the reduced features set had a slightly better performance,
compared to the CT-DRAGON, for the prediction of good and
miserable outcome. Due to the limited parameters, the reduced
features set is less vulnerable to overfitting, reflected by the
lower AIC and BIC values. However, the better performance
of the reduced features set may be biased as missing variables
in the CT-DRAGON score were higher, hence impairing its
performance. Most likely, the CT-DRAGON would have a better
discrimination than the reduced features set, if all data for the
score would always be available, which is unfortunately not the
case in a real-world setting.
The “simple variables model,” using age, pre-stroke functional
status, living alone pre-stroke, being able to walk unaided, lift
both arms off the bed and have a normal verbal Glasgow Coma
Score, has also been compared to the CT-DRAGON score (23).
Here the simplified score had a comparable performance for
predicting miserable outcome, compared with the CT-DRAGON
score. However, its six variables are comparable to the number of
variables of the CT-DRAGON score. In contrast, Wouters et al.
obtained a similar AUROC for amodel using only age andNIHSS
in prediction of good outcome (0.82 vs. 0.78 in our study) (24).
In their study the inclusion of the difference in NIHSS between
admission and after 24 h did not add much predictive power. The
variance of NIHSS in the prediction of outcome was 11–25% in
the analysis by Rost et al. (25).
Both the original CT-DRAGON score and reduced features
set were much better in predicting miserable outcome with
a high specificity. Since none of the prognostic scales are
yet incorporated in routine clinical practice, the combination
of age, pre-stroke modified Rankin Scale and NIHSS as a
reduced features set may therefore provide a good alternative.
It is immediately available, easier to implement and has a
better performance than the original CT-DRAGON, while
maintaining an excellent specificity in predicting miserable
outcome. However, dynamic predictive models require machine
learning techniques to be built, deployed and monitored over
time. This makes these dynamic models far less intuitive and
practical than rigid scoring systems.
This study has several limitations. First, the monocentric
design and the retrospective analysis of the prospectively
collected data prevent to make definitive conclusions on the
predictive performance of the reduced features set. Second, there
was a major bias due to the absence of the outcome, mRS
at 3 months, in about a quarter of the patients. Certainly, if
the outcome assessment would have differed among patient
subpopulations, this may have further amplified the bias.
Third, the inclusion of the patients who did not receive
either thrombolysis or thrombectomy may have affected the
performance of both scoring systems, as the reasons for
abstinence of therapy have varied strongly. However, the aim of
this study was the validation of a “score” with the knowledge
available during the admission to the emergency department.
Therefore, the reduced features set should still be validated
prospectively in a large multicentric study using real-world data.
To do this the reduced features set needs to be either converted
in an intuitive, clinically comprehensible score or validated as
a dynamic predictive model, requiring the continuous use of
machine learning techniques. Another drawback of the latter
model is the lack of a formal, explicit definition and the absence
of an intuitive, easily comprehensible attribution of points,
which are the cornerstones of rigid scoring systems. Fourth, the
difference in performance between the CT-DRAGON score and
the reduced features set was attenuated in the analysis of the
subgroup in which all data were available. This points to an
inherent bias against the CT-DRAGON score, due to its more
pronounced vulnerability to missing data.
Finally, prediction of outcome at population level, is not
equal to its performance in an individual patient. Furthermore,
prognostication at individual patient level with the aim of
therapeutic decision making may be unrealistic and not
applicable. Scores could be used for case-mix adjustments for
benchmarking purposes, driven by clinicians, in order tomonitor
quality of care over time and to compare outcomes among
different centers.
In conclusion, a reduced features set using the readily
obtainable parameters age, pre-stroke functional status and
stroke severity can reasonably predict functional outcome and
is a promising tool for case-mix adjustments in the purpose
of benchmarking.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Ziekenhuis Oost-Limburg, Secretariaat
Comité Medische Ethiek Schiepse Bos 6, 3600 GENK
ec.submission@zol.be. Written informed consent for
participation was not required for this study in accordance
with the national legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS
AL participated in the design of the study and analysis plan,
checked the database for accuracy and exported the data for
statistical analysis, performed the statistical analyses, and drafted
the manuscript. JG drafted the manuscript. LE supervised patient
recruitment, participated in the design of the study, and revising
the manuscript for important intellectual content. AW, LS,
SVB, and PV supervised patient recruitment and revising the
manuscript for important intellectual content. PW, SVP, and JV
revising the manuscript for important intellectual content. LD
checked the database for accuracy and revising the manuscript
for important intellectual content. EV follow-up of patients,
checked the database for accuracy, and revising the manuscript
for important intellectual content. SVC participated in the design
of the study and drafted themanuscript. DM conceived the study,
Frontiers in Neurology | www.frontiersin.org 7 July 2020 | Volume 11 | Article 718
Lesenne et al. Comparison CT-DRAGON/Reduced Features in Stroke
study design and analysis plan, performed the statistical analyses,
and drafted the manuscript. All authors read and approved the
final manuscript.
FUNDING
This work was supported by Interreg/SafePAT: project
number Euregio Maas-Rijn EMR90, Province of Limburg
Belgium, Limburg Clinical Research Center (LCRC) -
Anaesthesiology/Neurology Programme.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fneur.
2020.00718/full#supplementary-material
REFERENCES
1. GBD 2016 Stroke Collaborators. Global, regional, and national
burden of stroke, 1990-2016: a systematic analysis for the Global
Burden of Disease Study 2016. Lancet Neurol. (2019) 18:439−58.
doi: 10.1016/51474-4428(19)30034-1
2. Drozdowska BA, Singh S, Quinn TJ. Thinking about the future: a
review of prognostic scales used in acute stroke. Front Neurol. (2019)
10:274. doi: 10.3389/fneur.2019.00274
3. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al.
Randomized assessment of rapid endovascular treatment of ischemic stroke.
N Engl J Med. (2015) 372:1019–30. doi: 10.1056/NEJMoa1414905
4. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al.
Thrombectomywithin 8 hours after symptom onset in ischemic stroke.NEngl
J Med. (2015) 372:2296–306. doi: 10.1056/NEJMoa1503780
5. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al.
Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit
and infarct. N Engl J Med. (2018) 378:11–21. doi: 10.1056/NEJMoa1706442
6. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-
retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.N Engl
J Med. (2015) 372:2285–95. doi: 10.1056/NEJMoa1415061
7. BerkhemerOA, Fransen PS, BeumerD, van den Berg LA, LingsmaHF, YooAJ,
et al. A randomized trial of intraarterial treatment for acute ischemic stroke.
N Engl J Med. (2015) 372:11–20. doi: 10.1056/NEJMoa1411587
8. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al.
Endovascular therapy for ischemic stroke with perfusion-imaging selection.N
Engl J Med. (2015) 372:1009–18. doi: 10.1056/NEJMoa1414792
9. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S,
et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion
imaging. N Engl J Med. (2018) 378:708–18. doi: 10.1056/NEJMoa1713973
10. Fahey M, Crayton E, Wolfe C, Douiri A. Clinical prediction
models for mortality and functional outcome following ischemic
stroke: a systematic review and meta-analysis. PLoS ONE. (2018)
13:e0185402. doi: 10.1371/journal.pone.0185402
11. Strbian D, Meretoja A, Ahlhelm FJ, Pitkaniemi J, Lyrer P,
Kaste M, et al. Predicting outcome of IV thrombolysis-treated
ischemic stroke patients: the DRAGON score. Neurology. (2012)
78:427–32. doi: 10.1212/WNL.0b013e318245d2a9
12. Strbian D, Seiffge DJ, Breuer L, Numminen H, Michel P,
Meretoja A, et al. Validation of the DRAGON score in 12
stroke centers in anterior and posterior circulation. Stroke. (2013)
44:2718–21. doi: 10.1161/STROKEAHA.113.002033
13. Cooray C, Mazya M, Bottai M, Dorado L, Skoda O, Toni D,
et al. External validation of the ASTRAL and DRAGON scores
for prediction of functional outcome in stroke. Stroke. (2016)
47:1493–9. doi: 10.1161/STROKEAHA.116.012802
14. Wang A, Pednekar N, Lehrer R, Todo A, Sahni R, Marks S, et al. DRAGON
score predicts functional outcomes in acute ischemic stroke patients receiving
both intravenous tissue plasminogen activator and endovascular therapy. Surg
Neurol Int. (2017) 8:149. doi: 10.4103/2152-7806.210993
15. Ovesen C, Christensen A, Nielsen JK, Christensen H. External validation
of the ability of the DRAGON score to predict outcome after thrombolysis
treatment. J Clin Neurosci. (2013) 20:1635–6. doi: 10.1016/j.jocn.2013.04.023
16. Giralt-Steinhauer E, Rodriguez-Campello A, Cuadrado-Godia E, Ois
A, Jimenez-Conde J, Soriano-Tarraga C, et al. External validation of
the DRAGON score in an elderly Spanish population: prediction of
stroke prognosis after IV thrombolysis. Cerebrovasc Dis. (2013) 36:110–
4. doi: 10.1159/000352061
17. Zhang X, Liao X, Wang C, Liu L, Wang C, Zhao X, et al. Validation of the
DRAGON score in a chinese population to predict functional outcome of
intravenous thrombolysis-treated stroke patients. J Stroke Cerebrovasc Dis.
(2015) 24:1755–60. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.046
18. Turc G, Apoil M, Naggara O, Calvet D, Lamy C, Tataru AM, et al.
Magnetic resonance imaging-DRAGON score: 3-month outcome prediction
after intravenous thrombolysis for anterior circulation stroke. Stroke. (2013)
44:1323–8. doi: 10.1161/STROKEAHA.111.000127
19. Turc G, Aguettaz P, Ponchelle-Dequatre N, Henon H, Naggara O, Leclerc
X, et al. External validation of the MRI-DRAGON score: early prediction
of stroke outcome after intravenous thrombolysis. PLoS ONE. (2014)
9:e99164. doi: 10.1371/journal.pone.0099164
20. Ben Hassen W, Raynaud N, Bricout N, Boulouis G, Legrand L, Ferrigno M,
et al. MT-DRAGON score for outcome prediction in acute ischemic stroke
treated by mechanical thrombectomy within 8 hours. J Neurointerv Surg.
(2019) 12:246–51. doi: 10.1136/neurintsurg-2019-015105
21. Lundervold AS, Lundervold A. An overview of deep learning
in medical imaging focusing on MRI. Z Med Phys. (2019)
29:102–27. doi: 10.1016/j.zemedi.2018.11.002
22. Soffer S, Ben-Cohen A, Shimon O, Amitai MM, Greenspan H,
Klang E. Convolutional neural networks for radiologic images: a
radiologist’s guide. Radiology. (2019) 290:590–606. doi: 10.1148/radiol.2018
180547
23. Seiffge DJ, Karagiannis A, Strbian D, Gensicke H, Peters N, Bonati LH,
et al. Simple variables predict miserable outcome after intravenous
thrombolysis. Eur J Neurol. (2014) 21:185–91. doi: 10.1111/ene.
12254
24. Wouters A, Nysten C, Thijs V, Lemmens R. Prediction of outcome in
patients with acute ischemic stroke based on initial severity and improvement
in the first 24 h. Front Neurol. (2018) 9:308. doi: 10.3389/fneur.2018.
00308
25. Rost NS, Bottle A, Lee JM, Randall M, Middleton S, Shaw
L, et al. Stroke severity is a crucial predictor of outcome: an
international prospective validation study. J Am Heart Assoc. (2016)
5:e002433. doi: 10.1161/JAHA.115.002433
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Lesenne, Grieten, Ernon, Wibail, Stockx, Wouters, Dreesen,
Vandermeulen, Van Boxstael, Vanelderen, Van Poucke, Vundelinckx, Van Cauter
and Mesotten. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 8 July 2020 | Volume 11 | Article 718
